Onconova Therapeutics Inc
NASDAQ:TRAW

Watchlist Manager
Onconova Therapeutics Inc Logo
Onconova Therapeutics Inc
NASDAQ:TRAW
Watchlist
Price: 2.24 USD -3.86%
Market Cap: 17.9m USD

Intrinsic Value

The intrinsic value of one TRAW stock under the Base Case scenario is 0.71 USD. Compared to the current market price of 2.24 USD, Onconova Therapeutics Inc is Overvalued by 68%.

The Intrinsic Value is calculated as the average of DCF and Relative values:

TRAW Intrinsic Value
0.71 USD
Overvaluation 68%
Intrinsic Value
Price
Worst Case
Base Case
Best Case

Valuation History
Onconova Therapeutics Inc

What is Valuation History?
Ask AI Assistant
What other research platforms think about TRAW?

Let our AI compare Alpha Spread’s intrinsic value with external valuations from Simply Wall St, GuruFocus, ValueInvesting.io, Seeking Alpha, and others.

Discover External Valuations
Why is TRAW valued this way?

Let our AI break down the key assumptions behind the intrinsic value calculation for Onconova Therapeutics Inc.

Explain Valuation
Compare TRAW to

Fundamental Analysis

Company Overview
Loading...
Economic Moat
Loading...
Earnings Call
Loading...
Management
Loading...
Contacts
Loading...
How do you feel about TRAW?
Bearish
Neutral
Bullish
Financials
Annual
Quarterly
TTM
Annual
Quarterly
TTM

Revenue & Expenses Breakdown
Onconova Therapeutics Inc

Balance Sheet Decomposition
Onconova Therapeutics Inc

Current Assets 9.6m
Cash & Short-Term Investments 6.4m
Receivables 2m
Other Current Assets 1.2m
Non-Current Assets 2.8m
PP&E 7k
Intangibles 2.6m
Other Non-Current Assets 240k
Current Liabilities 7.9m
Accounts Payable 5.1m
Accrued Liabilities 2.6m
Other Current Liabilities 139k
Non-Current Liabilities 11k
Other Non-Current Liabilities 11k
Efficiency

Free Cash Flow Analysis
Onconova Therapeutics Inc

Last Value
3-Years Average
FCF Margin
Conversion Rate

Earnings Waterfall
Onconova Therapeutics Inc

Revenue
2.8m USD
Operating Expenses
-18.6m USD
Operating Income
-15.8m USD
Other Expenses
109.1m USD
Net Income
93.4m USD
Fundamental Scores

TRAW Profitability Score
Profitability Due Diligence

Onconova Therapeutics Inc's profitability score is 67/100. The higher the profitability score, the more profitable the company is.

Exceptional 3Y Average ROIC
Exceptional 3Y Average ROE
Exceptional ROIC
Exceptional ROE
67/100
Profitability
Score

Onconova Therapeutics Inc's profitability score is 67/100. The higher the profitability score, the more profitable the company is.

TRAW Solvency Score
Solvency Due Diligence

Onconova Therapeutics Inc's solvency score is 49/100. The higher the solvency score, the more solvent the company is.

Low D/E
Long-Term Solvency
Short-Term Solvency
Low Altman Z-Score
49/100
Solvency
Score

Onconova Therapeutics Inc's solvency score is 49/100. The higher the solvency score, the more solvent the company is.

Wall St
Price Targets

TRAW Price Targets Summary
Onconova Therapeutics Inc

Wall Street analysts forecast TRAW stock price to rise over the next 12 months.

According to Wall Street analysts, the average 1-year price target for TRAW is 8.16 USD with a low forecast of 8.08 USD and a high forecast of 8.4 USD.

Lowest
Price Target
8.08 USD
261% Upside
Average
Price Target
8.16 USD
264% Upside
Highest
Price Target
8.4 USD
275% Upside
View Analyst Estimates
View Analyst Estimates

Dividends

Onconova Therapeutics Inc
does not pay dividends
Shareholder Yield

Current shareholder yield for TRAW is .

Shareholder yield represents the total return a company provides to its shareholders, calculated as the sum of dividend yield, buyback yield, and debt paydown yield. What is shareholder yield?

Shareholder Yield
Dividend Yield
No dividends
Buyback Yield
Lowest
Average
Highest
Debt Paydown Yield
Lowest
Average
Highest

Competitive Landscape

Company Market Cap Intrinsic Valuation Profitability Solvency Price Change
1Y 3Y 5Y
What is the Intrinsic Value of one TRAW stock?

The intrinsic value of one TRAW stock under the Base Case scenario is 0.71 USD.

Is TRAW stock undervalued or overvalued?

Compared to the current market price of 2.24 USD, Onconova Therapeutics Inc is Overvalued by 68%.

Back to Top